20
Participants
Start Date
March 1, 2021
Primary Completion Date
April 10, 2021
Study Completion Date
April 10, 2021
Period 1: AT-527 550 mg
AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
Period 2: carbamazepine
Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
Period 3: AT-527 550 mg + carbamazepine
AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
Period 3: AT-527 1100 mg + carbamazepine
AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
Atea Study Site, Montreal
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Atea Pharmaceuticals, Inc.
INDUSTRY